Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAX) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 45,400 shares, a growth of 6.3% from the May 31st total of 42,700 shares. Based on an average trading volume of 45,900 shares, the days-to-cover ratio is presently 1.0 days.

Institutional Trading of Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. LM Advisors LLC purchased a new position in shares of Evaxion Biotech A/S (NASDAQ:EVAX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 337,336 shares of the company’s stock, valued at approximately $231,000. LM Advisors LLC owned about 8.90% of Evaxion Biotech A/S at the end of the most recent reporting period. 11.04% of the stock is owned by institutional investors and hedge funds.

Evaxion Biotech A/S Trading Up 8.6 %

EVAX stock opened at $3.15 on Friday. The company has a market cap of $17.04 million, a price-to-earnings ratio of -0.73 and a beta of -0.28. Evaxion Biotech A/S has a 12 month low of $2.26 and a 12 month high of $13.82. The firm has a 50-day moving average of $3.47 and a two-hundred day moving average of $4.39.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its quarterly earnings data on Tuesday, May 28th. The company reported $0.03 EPS for the quarter. The business had revenue of $0.05 million during the quarter. As a group, equities analysts forecast that Evaxion Biotech A/S will post -0.1 earnings per share for the current year.

Analyst Ratings Changes

EVAX has been the topic of a number of research analyst reports. LADENBURG THALM/SH SH raised Evaxion Biotech A/S from a “neutral” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Tuesday, April 2nd. HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Evaxion Biotech A/S in a research note on Tuesday, June 4th.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.